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Resistance to the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has been attributed solely
to mutations in BTK and related pathway molecules. Using whole-exome and deep-targeted
sequencing, we dissect evolution of ibrutinib resistance in serial samples from ﬁve chronic
lymphocytic leukaemia patients. In two patients, we detect BTK-C481S mutation or multiple
PLCG2 mutations. The other three patients exhibit an expansion of clones harbouring del(8p)
with additional driver mutations (EP300, MLL2 and EIF2A), with one patient developing trans-
differentiation into CD19-negative histiocytic sarcoma. Using droplet-microﬂuidic technology
and growth kinetic analyses, we demonstrate the presence of ibrutinib-resistant subclones
and estimate subclone size before treatment initiation. Haploinsufﬁciency of TRAIL-R, a
consequence of del(8p), results in TRAIL insensitivity, which may contribute to ibrutinib
resistance. These ﬁndings demonstrate that the ibrutinib therapy favours selection and
expansion of rare subclones already present before ibrutinib treatment, and provide insight
into the heterogeneity of genetic changes associated with ibrutinib resistance.
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B
-cell receptor (BCR) signalling is a critical growth and
survival pathway in several B-cell malignancies, including
chronic lymphocytic leukaemia (CLL)1. BCR signalling
can be abrogated by novel kinase inhibitors that target the
BCR-associated kinases SYK2, Bruton’s tyrosine kinase (BTK)3
and PI3Kd (ref. 4). The BTK inhibitor ibrutinib is a small
molecule that inactivates BTK through irreversible covalent
binding to Cys-481 within the ATP-binding domain of BTK5.
In a recent trial in patients with relapsed/refractory CLL, ibrutinib
induced an overall response rate of 71% and an estimated
progression-free survival rate of 75% after 26 months of therapy3.
However, a small fraction of patients develop progressive CLL
after initially responding to ibrutinib3. Among these, patients
carrying BTK mutations at the ibrutinib-binding site (C481S) or
affecting the BCR-signalling-related molecule PLCg2 (R665W,
L845F and S707Y) were recently highlighted6,7.
The ability of cancer cells to evolve and adapt to targeted
therapies is a challenge that limits treatment success and
durability of responses. Whole-exome sequencing (WES), along
with analyses of clonal heterogeneity and clonal evolution in CLL,
can provide insight into emergence and expansion of subclones
that carry driver mutations (for example, SF3B1 and TP53) under
therapeutic pressure8. To determine the pattern of clonal
evolution in ibrutinib-resistant CLL patients, we performed a
longitudinal genomic investigation of ﬁve CLL patients who
achieved partial remissions and later experienced disease
progression. Here we demonstrate that ibrutinib therapy
favours the selection and expansion of CLL subclones, carrying
del(8p) with additional driver mutations in three different
patients. Our studies provide insight into dynamic changes in
clonal architecture during ibrutinib therapy, as well as potential
alternative mechanisms of resistance. These ﬁndings are of
particular interest, given the increasing clinical use of this BTK
inhibitor.
Results
CLL relapse following ibrutinib therapy in Patients 1–4.
Ibrutinib therapy generally is highly effective, and responses are
durable in the vast majority of patients. However, some patients
who initially respond the CLL eventually relapse because of the
development of resistance, and presence of del(17p), especially in
combination with other complex cytogenetic alterations, has been
reported to predispose CLL patients for development of
resistance9. In patients with relapsed/refractory CLL, the reported
rate of ibrutinib resistance at 26 months was 13% (ref. 3) or 7.5%
at a median follow-up of 16.8 months (ref. 10). Five patients from
these early clinical trials were characterized in this report. At
ibrutinib treatment initiation, Patients 1–4 had advanced stage
CLL (Rai stage 3–4; Table 1). Patients 1 and 2 had relapsed
disease after ﬂudarabine, cyclophosphamide and rituximab (FCR)
frontline therapy, while Patients 3 and 4 had received multiple
lines of prior therapy. CLL samples from all patients harboured
high-risk cytogenetic abnormalities (Patients 1 and 3 with
del(17p) and Patients 2 and 4 with complex cytogenetic
including del(11q) and del(17p). As the best response to
ibrutinib-based therapy, all four experienced partial remissions.
Patient 1 demonstrated normalization of haematologic
parameters after 183 days, with persistent bone marrow disease
(12% residual CLL cells after 448 days on ibrutinib). Patient 2 had
normalization of haematologic parameters after 87 days with
resolution of lymphadenopathy and splenomegaly, but persistent
marrow disease (29% residual CLL cells). Patient 3 achieved a
410-fold reduction but persistently elevated absolute lymphocyte
counts (ALCs) of B15,000 ml 1. Patient 4 had normalization of
haematologic parameters with resolution of lymphadenopathy
and splenomegaly, but persistent lymphocytosis and marrow
disease. Progressive disease (PD) on ibrutinib therapy,
characterized by increases in lymphocyte counts with a short
lymphocyte-doubling time (o3 months), along with anaemia,
thrombocytopaenia and neutropaenia, and recurrence of
lymphadenopathy and splenomegaly, was noted after 983, 176
and 554 days, respectively, in Patients 1–3. Patient 4 developed
progressive lymphadenopathy, anaemia and thrombocytopaenia
without worsening lymphocytosis after 669 days of ibrutinib
therapy. Patients 1 and 3 proceeded to other forms of therapy,
including anti-CD20 monoclonal antibodies and alternative
kinase inhibitors, and were doing well at the time of
manuscript preparation (one in remission, one with stable
disease), whereas Patient 2 expired from sepsis 63 days after
ibrutinib discontinuation, and Patient 4 expired from a
haemorrhage 34 days after ibrutinib discontinuation.
CLL progression interrelates with marked clonal evolution.
WES and copy number analysis were performed on two to ﬁve
serial peripheral blood CLL samples per patient, from which
detection of each somatic mutation and inference of its cancer cell
fraction (CFF) were undertaken (Supplementary Data 1 and
Supplementary Table 1), with the exception of Patient 4, from
whom only one sample at time of relapse was available.
Patients 1–3 demonstrated distinct patterns of clonal evolution
following exposure to ibrutinib. Patient 1’s leukaemia (Fig. 1a,b)
was ﬁrst studied before starting frontline chemoimmunotherapy
with FCR 3 years before the start of ibrutinib therapy. The
pre-FCR leukaemic population was composed predominantly of a
clone harbouring a mutation in SF3B1 (pG742D), which was
eradicated by FCR therapy, and replaced with a clone harbouring
biallelic inactivation of TP53, trisomy 12 and a new mutation in
SF3B1 (p.K666T; cancer cell fraction (CCF) of 74%). This new
clone was present at the time of ibrutinib initiation. Samples
during ibrutinib therapy were collected 1, 2 and 2.7 years after
initiating therapy. After 2 years of continuous ibrutinib treatment,
we observed the emergence of four PLCG2 mutations (S707F,
M1141R, M1141K and D993H) whose expansion involved the
entire sample by 2.7 years and was associated with a rapid rise in
ALCs. All of the detected PLCG2mutations were novel6, although
a mutation at the S707 site has been previously implicated in
ibrutinib resistance (S707Y, ref. 6) and has been shown in vitro to
disrupt an auto-inhibitory SH2 domain of PLCG2 (ref. 11).
We conﬁrmed that these represented four distinct subclones
by targeted mutation detection in single cells (Fig. 1c and
Supplementary Figs 1 and 2).
We obtained estimates for the absolute numbers of cells in each
subclone at each time point by integrating CCF with ALC
information (Methods). A model assuming stable growth rates of
the clones throughout the period of ibrutinib therapy ﬁts the ALC
counts well, and provided estimates of clonal growth rates during
treatment. In comparison with the previously estimated growth
rate of CLL cells in a heterogeneous group of patients ranging
from  0.29 to 0.71% per day12, the dominant clone at the start
of ibrutinib therapy (clone 4, Fig. 1d) was estimated to decline at a
rate of 0.2% (±0.2%) per day, while its progeny clones containing
the PLCG2 mutation grew at a rate of 1.5–1.9%±0.1–0.2% per
day. By extrapolating the growth rate back to the time of ibrutinib
initiation, we estimated that these four clones were already
present at the initiation of therapy (clone size ranging from 140 to
27,000 cells; Fig. 1e).
The clinical course of Patients 2 and 3 was notable for a
shorter interval until disease progression, which suggests different
evolutionary dynamics and resistance proﬁles13. Indeed, in these
patients no mutations in BTK or PLCG2 were observed either by
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WES or by deep sequencing of the known hotspots (BTK C481
and PLCG2 R665), despite average sequencing depths of 1,172
(range 398–2,263) and 1,126 (range 354–2,105), respectively.
Instead, in the pre-treatment sample of both these patients, a
minor subclone harbouring a del(8p) was detected, and in both
instances the dominant clone at relapse was a progeny of
the del(8p)-positive minor subclone, after the acquisition of
additional putative driver mutations in EIF2A (ref. 14) and RPS15
(refs 15–17; Patient 2; Fig. 2a,b), and mutations in known
hotspots15 for the histone acetyltransferase EP300 (Y1397F) and
the chromatin regulator MLL2 (Q3892; Patient 3; Fig. 2d,e).
Growth kinetic analysis of Patient 2 showed the del(8p)-
containing subpopulation (clone 3) to have a comparable
decline rate as the dominant clone at the time of ibrutinib
initiation (clone 1; Fig. 2c). However, the progeny of clone 3,
which contained the additional mutations in EIF2A and RPS15
(clones 4 and 5), exhibited elevated estimated growth rates of
3.3% and 44.5% per day, respectively, and were estimated to
comprise a median of 87,000,000 (or 1 in 1,600) cells at treatment
initiation. Patient 3 demonstrated a similar picture (Fig. 2f), with
the progeny of the del(8p) cells, which contained mutations in
EP300 and MLL2, estimated to grow at a rate of B4% per day.
Together, these ﬁndings suggest that the shorter time-to-
ibrutinib-failure in Patients 2 and 3 compared with that in
Patient 1 was inﬂuenced by both the faster growth kinetics
and a larger starting population of resistant cells at treatment
initiation.
From Patient 4, only one sample at the time of relapse was
available, and hence it was not possible to follow changes in the
clonal dynamics in this patient. Nonetheless, in this patient,
the previously reported BTK-C481S mutation was detected by
WES, by deep sequencing at the time of relapse and by
RNA-sequencing (RNA-seq) of the same sample (Supplementary
Fig. 3A).
Detection of resistant subclones before ibrutinib therapy. To
experimentally conﬁrm the calculations of clone size at treatment
initiation, we developed an ultrasensitive approach that leverages
the ability of droplet-digital ampliﬁcation technology to evaluate
single cells at high throughput. Although bulk quantitative
reverse transcriptase PCR (qRT–PCR) of the mutated allele can
detect rare mutated transcripts, it cannot provide information on
the actual number of affected cells. Deep-targeted sequencing can
only affordably detect alleles down to 1 in 100 or 1,000 cells, but is
prohibitively expensive for detection of rarer events. Droplet
technology, on the other hand, can compartmentalize single cells
at very high throughputs (43,000 per second) inside individual
‘reactors’ where enzymatic reactions such as RT–PCR can be
performed on each cell.
To reliably detect rare mutation-bearing cells, we devised a
two-stage ampliﬁcation and quantiﬁcation approach (Fig. 3a),
focusing on transcripts rather than DNA since the likelihood of
single-cell drop-out would be less because of greater transcript
abundance. The ﬁrst stage focuses on the sensitive detection of
cDNA from cells harbouring the speciﬁed mutated allele. Single
cells are encapsulated in droplets, wherein they undergo lysis and
the released mutated transcript can efﬁciently undergo allele-
speciﬁc RT–PCR (Fig. 3b,c, Supplementary Fig. 3B and
Supplementary Table 5). For cell populations of 1 in 103
leukaemia cells or greater, we estimated that this ﬁrst stage of
processing would be sufﬁcient for detection of single mutated
cells. Indeed, for Patients 2 and 3, we could detect small cell
populations bearing mutations associated with the resistant
subclone within the pre-treatment cells, but not in peripheral
blood mononuclear cell (PBMC) from normal adult donors
(Fig. 3d). Furthermore, these mutation-bearing cells were
expanded in number at the time of relapse (Supplementary
Fig. 4A). For Patient 2, we detected the presence of mutated
RP515 in 0.06% of pre-treatment cells (calculated previously to be
0.06%), while for Patient 3 we detected mutated DGKA in 0.15%
cells (not modelled mathematically previously because of too few
serial samples). Both measurements were within 1–2 orders of
magnitude of detection by deep-targeted sequencing of these
mutations (0.57% for Patient 2/mutated RPS15; 0.07% for Patient
3/mutated DGKA; Supplementary Data 1).
For the detection of rarer populations (such as for the
PLCG2-M1141R mutation in the pre-treatment sample of Patient
1, calculated to be in 1 in 6 million cells (conﬁdence interval: 1 in
70 million to 1 in 6 million)), we further added the second-stage
detection procedure. In this second stage, pooled mutated
amplicons were re-encapsulated using a Poisson distribution to
ensure that fewer than 30% of droplets contain templates.
Following digital PCR of the encapsulated templates, the
bright droplets were counted using ﬂuorescence detection
(Supplementary Fig. 4B). For PLCG2-M1141R, we generated a
standard curve from PBMC spiked with known numbers of cells
from the 30,019 cell lines, engineered to stably express mutated
PLCG2-M1141R, and we could reliably detect 1 in 104, 105 and
106 cells with the PLCG2 mutation compared with 106 cells
without the mutation, or the negative water control. In this
manner, we conﬁrmed detection of 1 in 500,000 (0.0002%) pre-
treatment cells of Patient 1 with mutated PLCG2-M1141R—of
similar order of magnitude as our mathematical calculations.
Table 1 | Patient characteristics.
Pt
number
Age (years)/
gender/Rai stage
Prior therapy Pre-ibrutinib FISH
cytogenetics
IGHV
(M, U)
Treatment Best response
to ibrutinib
Time to PD
on ibrutinib
1 59/M Rai III FCR del (17p), del (13q) ND Ibrutinib PR 983
2 36/F Rai IV FCR, RþHDMP del (11q)* U Ibrutinib
þ rituximab
PR 176
3 85/F Rai IV R, BR, CLB, RþHDMP del (17p), del (13q),
trisomy 12*
U Ibrutinib PR 554
4 58/M Rai IV FCR, FR, CHOP, allo-Tx, BR,
revlimid, ofatumumab
del (17p), del (11q),
del (13q)*
U Ibrutinib PR 669
5 58/M Rai II FCR, F, R, B del (11q), del (13q) U Ibrutinib PR 392
allo-Tx, allogeneic stem cell transplantation; BR, bendamustine, rituximab; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; CLB, chlorambucil; F, female; (prior therapy) FCR,
ﬂudarabine, cyclophosphamide, rituximab; FISH, ﬂuorescence in situ hybridization; F, R, B, single-agent ﬂudarabine, rituximab, bendamustine; FR, ﬂudarabine, rituximab; IGHV, immunoglobulin
heavy-chain variable region genes; M, male; M, mutated; ND, not determined; PD, progressive disease; (best response) PR, partial remission; Pt, patient; RþHDMP, rituximabþ high-dose
methylprednisolone; U, unmutated.
*Complex cytogenetics pre-ibrutinib: Pt 2: 46,XX,del(2q37),del(6q21q23), add(7q36),del(11q21q25); Pt 3: 45,X,add(X)(q24), add(6p23), add(12p13), del(17p11.2), -21; Pt 4: 45,XY,del(6q13q23),
add(8p21), del(11q21q24), -17,-18,þmar[5].
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Altogether, these results conﬁrm that pre-treatment samples
already contain resistant subclones before the initiation of
targeted inhibition of BTK, albeit at rare frequencies.
Trans-differentiation from CLL to histiocytic sarcoma. Patient
5 also demonstrated clonal evolution, but his relapse trajectory
was markedly different. At diagnosis, 6 years before the initiation
of ibrutinib, this patient presented with bulky lymphadenopathy
and del(11q) and del(13q) using ﬂuorescence in situ hybridization
(FISH) analysis. He shortly, thereafter, was treated with frontline
FCR, relapsed 2 years later and was re-treated with multiple
courses of single-agent ﬂudarabine, rituximab and bendamustine,
without any durable responses. Therefore, he proceeded to
ibrutinib therapy, and achieved a partial remission, characterized
by normalization of the ALC after a transient increase in
lymphocytosis and rapid major reduction of his bulky lymph
nodes. While still in haematologic remission, he presented on day
392 with a 1-week history of fatigue, malaise, muscle and joint
aches, night sweats and low-grade fevers. Evidence for CLL
relapse or Richter’s transformation was absent since recurrence of
bulky lymphadenopathy was not noted on physical examination
or CT scans (Fig. 4a), and histopathology examination of
bone marrow testing revealed only 2% involvement by CLL
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Figure 1 | Evidence of clonal evolution with late disease progression following ibrutinib. (a) White blood cell counts and treatment course of Patient 1.
Peripheral blood specimens were sampled at ﬁve time points (indicated by arrows), and CLL cells underwent whole-exome sequencing. Following somatic
mutation calling, CCF of somatic variants was inferred by ABSOLUTE analysis of deep-sequencing data of the detected mutations (see Supplementary
Figs 1 and 2). Asterisk indicates that this sample had less purity, and hence clone sizes are estimates. (b) A phylogenetic tree was inferred based on
PHYLOGIC, a novel algorithmic extension of ABSOLUTE. Driver mutations associated with each clone are indicated (a complete listing of somatic
mutations and allelic fractions found for each clone in Supplementary Table 2 and Supplementary Figs 1 and 2). (c) Multiplexed detection of somatic
mutations in 134–172 single cells of Patient 1 at TP1, TP2 (pre-ibrutinib) and TP5 (ibrutinib relapse). Between all three time points, shifting cell
subpopulations with SF3B1 mutation are observed. At TP5, SF3B1-K666T is detected in all cells, while the various PLCG2 mutations are detected in distinct
subpopulations. Single-cell expression levels of wild-type (WT) and mutated (MUT) PLCG2 are shown in Supplementary Fig. 3B. (d) The clonal kinetics
during ibrutinib treatment. Filled circles—measurement of the number of cells comprising each subclone at each time point based on the subclone CCF and
the corresponding ALCs. Measurements are shown with 95% conﬁdence interval (CI) obtained from posterior distributions of CCFs. Empty circles—upper
bound estimates (1% of total CLL cells) for subclones that were below the detection threshold of targeted deep sequencing. Solid lines denote predicted
kinetics for clones detected on at least two measurements. Dashed lines represent kinetics with minimal absolute growth rates for clones detected in only
one measurement. (e) Extrapolation of clone size with 95% CI at the time of treatment initiation for the PLCG2-MUT subclones.
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cells (compared with 40% before starting ibrutinib therapy).
Laboratory studies demonstrated a normal ALC of 1,800 ml 1.
The patient was admitted for treatment of presumed systemic
infection and renal failure and received empiric antibiotics
and ﬂuid resuscitation, without improvement. Two days after
admission, he was transferred to the ICU for multiorgan
dysfunction and expired the same day. Autopsy revealed exten-
sive involvement of the liver, spleen, lung, kidney and multiple
lymph nodes with histiocytic sarcoma (HS). The neoplastic cells
were positive for monocyte/macrophage markers CD68 (PGM1)
and CD163, but negative for CD1a, CD30, CD5, CD15, CD3,
CD45 (LCA), CD19, S100 and PAX-5 (Fig. 4b). Immunoglobulin
heavy-chain variable region (IGHV) gene analysis of HS tissue,
which tested negative for any B cells with immunohistochemical,
revealed a clonal band (VH3-09), unmutated, which is the same
family and somatic mutation status (MS) as originally detected in
this patient’s CLL cells, indicating clonal relation between the
CLL and the HS.
Genetic dissection of clonal evolution in Patient 5. Three
distinct tissues from two time points were evaluated with WES
(Fig. 4c). Pre-treatment CLL DNA was extracted from the bone
marrow collected before ibrutinib therapy. The progression DNA
samples were extracted from lymph node and liver autopsy
samples, both of which were conﬁrmed to have involvement by
HIS. As germline comparison, DNA was extracted from the
uninvolved cardiac muscle. We found that all three samples
shared a common set of mutations (for example, ATM, BRAF
and del[11q]), indicative of a common ancestor of the CLL and
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Figure 2 | Clonal evolution with early disease progression following ibrutinib.White blood cell counts and treatment courses of Patients 2 (a) and 3 (d).
Peripheral blood specimens were sampled at serial time points (indicated by arrows), and CLL cells underwent whole-exome sequencing. Following somatic
mutation calling, CCFs of somatic variants were inferred by ABSOLUTE analysis (Supplementary Figs 1 and 2). The phylogenetic trees for Patients 2 (b) and
3 (e) were inferred based on Phylogic. Driver mutations associated with each clone are indicated (a complete list of somatic mutations and allelic fractions
found for each clone in Supplementary Table 2 and Supplementary Figs 1 and 2). Clonal kinetics during ibrutinib treatment for Patients 2 (c) and 3 (f).
Filled circles—measurements combining clonal fractions and ALC counts. Empty circles are upper bound estimates (1% of total CLL cells) for clones
that were below detection. Solid lines denote predicted kinetics for clones with at least two measurements. For Patient 2, dashed lines represent kinetics
with minimal absolute growth rates for clones with only one measurement, while for Patient 3 the dashed lines represent kinetics obtained from ﬁtting to
ALCs. Measurements are shown with 95% CI obtained from posterior distributions of CCFs. For Patient 3, we assumed clones 1 and 2 have the same rates
of decline and clones 4 and 5 have the same growth rates during treatment.
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HS, consistent with the IGHV analysis. A large CLL subclone
(CCF of 36%) distinguished by mutations in DMBX1 and
DNAJB14 gave rise to the HIS parent clone, which notably con-
tained del(8p) as well as an NRAS mutation. These mutations
deﬁne the HS parent as they were shared by HS cells in both
the liver and the lymph node samples. Finally, further clonal
diversiﬁcation was observed within the lymph node and the liver
samples. For example, all HS cells in the lymph node but not in
the liver had the HS parent mutations as well as an EP300
mutation (N1511S).
Apoptosis resistance in CLL samples with del(8p). Having
unexpectedly observed del(8p) in the resistance clone of three out
of ﬁve patients with ibrutinib relapse, we examined the genes in
this region more closely. The region of del(8p) in Patients 2, 3
and 5 encompassed tumour necrosis factor-related apoptosis-
inducing ligand-receptor (TRAIL-R) (Supplementary Fig. 5A,B),
and we observed a decrease in the TRAIL-R mRNA and protein
levels corresponding to an increase in the CCF of the del(8p)-
harbouring clone (Supplementary Table 3 and Supplementary
Fig. 5A). Previous reports have identiﬁed haploinsufﬁciency of
the TRAIL-R as a potential target of del(8p)18. Intriguingly,
a potential indirect mechanism that would link TRAIL resistance
to positive selection by the ibrutinib therapy is suggested by the
fact that TRAIL concentrations are higher in circulating blood
compared with the lymph node environment19(Supplementary
Fig. 5E). Ibrutinib therapy is known to mobilize CLL cells
from the lymph node and spleen to the periphery, resulting
in lymphocytosis6. Hence, a potential mechanism by which
haploinsufﬁciency of the TRAIL-R could provide a survival
advantage for CLL cells with this deletion is through the relative
insensitivity of del(8p) CLL cells to cell death in the periphery
once they are released from the lymph node and are exposed to
higher levels of TRAIL. We observed relatively stable high serum
levels of TRAIL over time in the CLL patients across the duration
of treatment with ibrutinib (Supplementary Fig. 5F).
To explore this possibility, we quantiﬁed TRAIL- and
ibrutinib-induced apoptosis in a mostly independent cohort of
six CLL samples with del(8p) and in nine non-del(8p) controls
(del(8p) status veriﬁed with FISH (Fig. 5a–c and Supplementary
Fig. 5D) from patients not previously treated with ibrutinib.
Treatment with ibrutinib (1 mM) resulted in a signiﬁcant decrease
in CLL cell viability in non-del(8p) controls (P¼ 0.02; one-sided
paired t-test) and to a lesser extent in del(8p) samples (P¼ 0.06i).
In contrast, treatment with TRAIL induced a signiﬁcant
difference in CLL cell viability only in the non-del(8p) samples
(Fig. 5c). Consistent with previous reports20, TRAIL treatment
could result in apoptosis or enhanced survival, yet a decrease in
viability was observed in a greater proportion of non-del(8p)
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Figure 3 | Droplet-based detection of resistance subclones at the time of treatment initiation. (a) Schema of the experimental workﬂow. (b) Speciﬁcity
of the mutation-detection primers visualized on an agarose gel in bulk cell line populations transfected to express minigenes encoding the WT versus
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samples (56% versus 17%). In fact, TRAIL treatment induced a
16% median decrease in viability in non-del(8p) controls
(P¼ 0.05; one-sided paired t-test) compared with only a 5%
median decrease in del(8p) CLL samples (P¼ 0.12). Hence,
monoallelic deletion of chromosome 8p was sufﬁcient to abrogate
the positive or negative effects of TRAIL on cell viability in vitro.
Combination treatment with TRAIL in the presence of ibrutinib
further signiﬁcantly reduced CLL cell viability in non-del(8p)
samples (P¼ 0.01; one-sided paired t-test). In contrast, there was
only a small, nonsigniﬁcant reduction in the median viability by
12% in del(8p) CLL samples (P¼ 0.13; one-sided paired t-test; see
Fig. 5c, lower panel). These data indicate that del(8p) confers
partial resistance to apoptosis in response to TRAIL or TRAIL in
combination with ibrutinib. Finally, we sought to determine
whether these differences in responses to TRAIL would be evident
in serial specimens from two patients developing resistance to
ibrutinib via expansion of the del(8p) clone. We therefore treated
specimens from Patients 2 and 3 with TRAIL and/or ibrutinib
(or staurosporine as control) and found the expected sensitivity
to TRAIL in the pre-treatment samples and resistance in the
relapse samples, conﬁrming the role of del(8p) in protection
from TRAIL-induced apoptosis (Fig. 5d and Supplementary
Fig. 6). Interestingly, ibrutinib-resistant CLL cells remained
staurosporine-sensitive, arguing against more general apoptosis
resistance and suggesting that kinase inhibitor therapy can further
be developed for targeting ibrutinib resistance.
Discussion
The foremost obstacle to effective targeted therapy is the
emergence of disease resistance through clonal evolution.
BCR-ABL kinase domain mutations in patients with CML, which
confer resistance to the tyrosine kinase inhibitor imatinib21, are
well-characterized examples for this mechanism. Reminiscent of
the imatinib experience, two reports recently highlighted point
mutations in BTK (C481S)6,7 that disrupt ibrutinib binding and
in its related pathway member PLCG2 (R665W, L845F, S707Y)6
that can activate the BCR pathway independently from BTK as
mechanisms of ibrutinib resistance.
An important question emerging from these data is whether
ongoing mutagenesis during ibrutinib therapy led to acquisition
of these resistance mutations, or whether this is rather because
of the expansion of pre-existing subclones under therapeutic
pressure. Previous studies failed to detect pre-treatment resistance
mutations6; however, these were likely limited by the ability of
current deep-sequencing approaches to detect minority resistant
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Figure 4 | Histiocytic sarcoma trans-differentiation of CLL during ibrutinib therapy. (a) Regression of lymph node (LN) disease, visualized with CTscan,
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(c) White blood cell counts and clinical course for Patient 5. Whole-exome sequencing and CCF measurements were made before ibrutinib initiation (TP1)
and from post-mortem specimens of the liver and LN (TP2). The fraction of cells that shared the mutations that deﬁne the histiocytic sarcoma parent
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populations. On the basis of an integrated investigation of the
clonal dynamics, growth rate kinetics and experimental detection
of rare mutation-bearing cell populations, our analyses support
the presence of substantial diversity of resistant subclones at
treatment initiation, in line with theoretical predictions22. In
particular, we observed that the genetic composition and kinetics
of ibrutinib resistance were dictated by clone size and growth rate
of the resistant cells, that is, the ﬁtness of the resistant clone in
relation to other sibling clones23.
Patient 1 was particularly exemplary: in this patient, we
identiﬁed four distinct PLCG2 mutations, conﬁrmed by RNA-seq
and deep-sequencing validation. Shifts in their relative proportion
suggest the presence of four distinct subclones, with distinct
growth rates. The relatively small proportion of these clones at
treatment initiation suggests either no ﬁtness advantage or a
minor ﬁtness advantage of these mutations in the absence of
ibrutinib, which became accentuated by ibrutinib therapy. This
patient’s leukaemia had another instance of convergent evolution
with clonal shifts in relation to prior FCR therapy, where a
clone containing a SF3B1 mutation was replaced by another
clone harbouring a different SF3B1 mutation (Fig. 1). This case
demonstrates the enormous amount of trial and error that occurs
in the process of cancer diversiﬁcation serving its ability to adapt
to therapy.
Notably, while the BTK-C481S and PLCG2 mutations were
found in two of ﬁve subjects, the remaining patients revealed
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following hybridization for probes speciﬁc for chromosome 8p21.3 (red) and chromosome 8 centromere (green), showing a CLL cell with a normal disomic
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(c) Primary CLL cells were isolated from peripheral blood and treated with ibrutinib (1 mM) and/or TRAIL (200ngml 1). Cell death was assessed with
Annexin V and propidium iodide (PI) staining and ﬂow cytometry. P-values calculated for absolute change in viability. In agreement with the known
pleiotropic effects of TRAIL on CLL cells20, we found that TRAIL treatment induced apoptosis in six out of nine of non-del(8p) samples, yet could also
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induced apoptosis and largely are ibrutinib-resistant, but remained sensitive to staurosporine. Cell viability measurements were equivalent whether based
on annexin V/PI or by live cell counts (Supplementary Fig. 6b).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11589
8 NATURE COMMUNICATIONS | 7:11589 | DOI: 10.1038/ncomms11589 | www.nature.com/naturecommunications
a diverse spectrum of mutations present in resistant cells,
illustrating the diversity of mutations participating in the disease
progression with ibrutinib therapy. The relapse clones of Patients
2, 3 and 5 arose from parent clones with large deletions of
chromosome 8p, previously described to be present in only 5% of
the CLL cases and associated with poor prognosis in CLL24,
especially in patients with del (17p)25. Del(8p) is also a recurrent
event in mantle cell lymphoma and other non-Hodgkin
lymphomas. As we previously reported, del(8p) likely is a CLL
driver that appears later in the evolutionary history of CLL8,24.
This large region encompasses deletions of the TRAIL receptor
gene loci18, which we conﬁrmed to be downregulated with
RNA-seq expression data and with direct ﬂow cytometric
detection of surface protein expression from Patients 2 and 3
(Supplementary Table 3 and Supplementary Fig. 5c). Monoallelic
deletion of TRAIL-R1/2 (TNFRSF10A/B, also called death
receptor 4/5 (DR4/DR5)) can antagonize TRAIL-induced
apoptosis in B-NHL18, suggesting that TRAIL-R1/2 may
function as tumour suppressors. Our functional data support
TRAIL receptor haploinsufﬁciency as a potential resistance
mechanism. We noted robust TRAIL-induced apoptosis in CLL
samples with intact 8p, but reduced or absent TRAIL-induced
apoptosis in samples with del(8p), demonstrating that monoallelic
deletion was sufﬁcient to abrogate the pro-apoptotic effects of
TRAIL. This was conﬁrmed in serial CLL cell samples from
Patients 2 and 3, where preserved sensitivity to TRAIL was noted
in a pre-treatment sample, and resistance to TRAIL in the relapse
sample (Fig. 5d). We also noted additive induction of CLL cell
apoptosis by TRAIL in the presence of ibrutinib; this combination
may merit further exploration in the clinic. Interestingly, the
analysis of clonal kinetics revealed that the del(8p) clones initially
also declined with ibrutinib therapy (albeit in a slower rate), and
subsequently were replaced by their more proliferative progeny,
containing additional somatic alterations. This raises the
intriguing hypothesis that, while del(8p) provides a ﬁtness
advantage in the absence of ibrutinib, it needs to cooperate
with additional lesions to achieve the resistant phenotype. For
example, we identiﬁed mutations in EP300, RPS15 orMLL2 in the
cells with del(8p). We recently identiﬁed mutations in RPS15
(all around a hotspot region) as novel signiﬁcantly recurrent
mutations in CLL in a series of 538 CLLs proﬁled by WES16.
In addition, Ljungstrom et al.17 further identiﬁed RPS15 as a
recurrently mutated gene in the setting of resistance/relapse
to ﬂudarabine-based chemotherapy. Of note, these authors
demonstrated that expression of mutant RPS15 revealed
defective regulation of endogenous p53 (with reduced
stabilization and increased p53 degradation) compared with
wild-type RPS15. Both MLL2 and EP300 have been identiﬁed as
signiﬁcantly mutated across cancers with known roles in
histone and chromatin regulation, respectively. How exactly the
particular functions of these driver alterations enable bypass of
BTK inhibition is unknown. We speculate that alteration of the
DNA-damage response and chromatin/histone biology are both
paths by which cellular ﬁtness of CLL cells are enhanced, and can
lead to BCR-signalling-independent growth.
HISs are myeloid tumours, which rarely evolve in patients
with B-NHL and CLL as a result of cross-lineage trans-
differentiation26. As in the case of Patient 5, these exceedingly
rare cases of HISs are clonally related to the B-cell malignancy
based on shared IGHV immunoglobulin gene rearrangements
and additional shared mutations. These cases have been
interpreted as signs of lineage plasticity of the underlying B-cell
neoplasm, a phenomenon that was originally recognized in
mouse models27. In these models, enforced expression of
the transcription factors C/EBPa and C/EBPb promoted
trans-differentiation of B cells into macrophages. In humans,
trans-differentiation of lymphoid malignancies was found to be
association with mutations of NRAS and BRAF. Chen et al.
described a case of Langerhans cell sarcoma, transdifferentiated
from CLL that carried a BRAF V600E mutation28. Buser et al.
reported about trans-differentiation of a T lymphoblastic
lymphoma into an indeterminate dendritic cell tumour carrying
a G13D mutation of the NRAS gene29. Interestingly, our patient
had both BRAF and NRAS mutations that may be involved in the
trans-differentiation process.
The fact that the CLL clone at the time of trans-differentiation
remained in remission is characteristic, as is the poor prognosis,
with survival generally of only days to weeks. This case of HIS
trans-differentiation, with tumour cells no longer dependent on
BCR signalling, indicates that ibruitinib resistance may be a more
complex process than initially thought, and this potent therapy
may serve as a strong evolutionary drive to differentiate away
from the B-cell identity and its accompanying dependency on
BCR signalling.
We propose a novel analytic framework that is widely
applicable across cancer—frequent serial clonal analysis can
inform us regarding the clone-speciﬁc decline/growth kinetics as
they occur in patients. This type of analysis provides vital
information regarding the ﬁtness of different genetic lesions with
and without therapy, which may be immensely beneﬁcial to the
design of the next generation of therapeutic approaches to
overcome the evolutionary capacity of cancer.
Methods
CLL samples from patients treated with ibrutinib. All ﬁve patients were treated
at MD Anderson Cancer Center (MDACC) and were enrolled on clinical trials
approved by and conducted in accordance with the Institutional Review Board
(IRB) of the University of Texas MDACC guidelines and with the principles of the
Declaration of Helsinki. Patients 1, 3, 4 and 5 were treated on a phase Ib/II
multicentre study of ibrutinib (NCT01105247), while Patient 2 was enrolled on a
single-centre phase II clinical trial of ibrutinib and rituximab (NCT01520519). For
NCT01105247, the reported rate of resistance at 26 months was 13% (n¼ 11)3. On
NCT01520519, the rate of resistance was 7.5% (n¼ 3) at a median follow-up of
16.8 months10.
Heparinized blood and/or tissue samples were collected after obtaining
informed consent according to the IRB guidelines before and after initiation of
ibrutinib therapy, and PMBCs from patient samples were isolated with Ficoll/
Hypaque density-gradient centrifugation, cryopreserved with 10% DMSO and
stored in vapour-phase liquid nitrogen until the time of analysis. For Patients 1–4,
non-lymphoid cells (neutrophils) were isolated by subjecting the non-PBMC cells
(following Ficoll separation) to hypotonic erythrocyte lysis30. For Patient 5, DNA
was extracted from 30-m sections collected from patient marrow biopsy specimens,
obtained as part of routine clinical care, or from formalin-ﬁxed, parafﬁn-embedded
(FFPE) liver, heart and lymph node at the time of autopsy.
FISH and IGHV analyses. The pre-treatment evaluation of all patients included
FISH for common CLL chromosome abnormalities by the MDACC clinical
laboratory, using a Vysis multicolour probe panel (Abbott Laboratories, Abbott
Park, IL) designed to provide simultaneous detection of the 11q22.3 (ATM gene)
region of chromosome 11; the 17p13.1 (TP53 gene) region of chromosome 17; the
alpha satellite, centromeric region of chromosome 12 (D12Z3); the D13S319 locus
(located between RB1 and D13S25 loci) in the 13q14.3 region of chromosome 13;
and the 13q34 region (LAMP1 gene) near the subtelomere of chromosome 13q in
two hybridizations (two and three probes per hybridization, respectively),
as previously described31. A total of 200 interphase cells were analysed for each
probe. Positive patient cases were those with 5% or more of cells with the
abnormality. Patients’ FISH results were categorized according to the Do¨hner
hierarchy32. Analysis of the MS of the IgVH MS was performed in the MDACC
clinical laboratory, according to the established protocols described before33.
To detect deletions of chromosome 8p, interphase FISH was performed on ﬁxed
cell pellets stored at  20 C, obtained from conventional cytogenetic analysis, or
cytospins. The cytospins were generated with 5 104 CLL cells (Shandon
cytospins; 700 r.p.m. for 5min) ﬁxed with methanol:acetone (3:1) at room
temperature for 10min and then washed with 70% ethanol. Hybridization, using a
probe cocktail consisting of Vysis LSI LPL probes targeting 8p21.3 (Abbott
Molecular, Des Plaines, IL) and Vysis CEP8 (D8Z2; Abbott Molecular), was
performed according to the manufacturer’s speciﬁcations. One hundred nuclei
were scored per slide. Cutoffs for detection of 8p deletion or monosomy 8 were
calculated using negative control specimens with matching karyotype information,
based on 3 s.d.’s from the mean. The speciﬁc cutoff for 8p21.3 deletion was 9.4%.
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Immunohistochemistry. Immunohistochemical stains were performed on FFPE
sections of tissue, or bone marrow core biopsies or clots of Patient 5 using the
avidin–biotin–peroxidase complex method and an automated immunostainer
(Ventana-Biotech, Tucson, AZ). The following antibodies were used:
CD1a(Leica Biosystems, Buffalo Grove, IL, cloneMTB1, prediluted), CD3
(Dako, Carpinteria, CA, clone N/A, dilution1:100), CD5(Labvision Thermo Fisher,
Fremont, CA, clone 4C7, dilution 1:20), CD15(BD Biosciences San Jose, CA, clone
MMA, dilution 1:40), CD19 (Dako, cloneLE-CD19, dilution 1:100), CD30
(Covance, Dedham, MA, cloneKi-1, dilution 1:80), CD45/LCA (Dako, clone
ZB11þPD 7/26, dilution 1:300), CD68/PGM1 (Dako, clone PGM1, dilution
1:450), CD163(Leica Biosystemsclone 10D6, dilution1:100), PAX-5(BD
Biosciences, clone 24, dilution 1:35) and S100 protein(BioGenex, Fremont, CA,
clone 15E2E2, dilution 1:900). All tissue sections underwent heat-induced antigen
retrieval before staining with antibodies. Sequence analysis of the IGHV gene
region in samples with histologic evidence of HIS (Patient 5) was performed on
DNA extracted from FFPE tissue sections. To determine the degree of somatic
mutation in the IGHV region of non-haematopoietic tissues, patient’s IGHV
sequences were aligned to germline sequences and the patient’s known previously
characterized IGHV sequence (VH3-09), using the international ImMunoGeneTics
information system and database tools (IMGT/V-Quest, http://imgt.org). As per
convention, the IGHV somatic MS was designated as unmutated if there was
Z98% homology, or as mutated if there was o98% homology to germline
sequences34.
Nucleic acid extraction and quality control. For Patients 1–4, genomic DNA was
extracted from CLL PBMC and matched neutrophils (Qiagen, Valencia, CA). DNA
analyses were carried out after informed consent under IRB-approved research
protocols between MDACC and the Broad Institute. Tumour and normal DNA
concentrations were measured using PicoGreen dsDNA Quantitation Reagent
(Invitrogen, Carlsbad, CA). For Patient 5 samples, parafﬁn was removed from
samples using Citrisolv and several ethanol washes, and then cells were lysed
overnight at 56 C DNA. After removal of DNA crosslinks through incubation at
90 C, DNA extraction was performed (QIAamp DNA FFPE Tissue Kit, Qiagen).
A minimum DNA concentration of 60 ngml 1 was required for sequencing35,36.
All Illumina sequencing libraries were created with the native DNA. The identities
of all tumour and normal DNA samples were conﬁrmed using mass spectrometric
ﬁngerprint genotyping of 24 common single-nucleotide polymorphisms (SNPs;
Sequenom, San Diego, CA). RNA from CLL—B cells was extracted using standard
protocols (RNAeasy kit, Qiagen).
Whole-exome sequencing. Library construction from CLL and matched germline
DNA of Patients 1–5 was performed as described in ref. 37, with the following
modiﬁcations: (i) initial genomic DNA input into shearing was reduced from 3 mg
to 10–100 ng in 50ml of solution; (ii) for adapter ligation, Illumina paired-end
adapters were replaced with palindromic forked adapters (from Integrated DNA
Technologies), with unique eight-base molecular barcode sequences included in the
adapter sequence to facilitate downstream pooling. With the exception of the
palindromic forked adapters, the reagents used for end repair, A-base addition,
adapter ligation and library enrichment PCR were purchased from KAPA
Biosciences in 96-reaction kits, (iii) during the post-enrichment solid-phase
reversible immobilization (SPRI) cleanup, elution volumes were reduced to 20 ml to
maximize library concentration, and a vortexing step was added to maximize the
amount of template eluted. Any libraries with concentrations below 40 ng ml 1
(per PicoGreen assay, automated on an Agilent Bravo) were considered failures
and reworked from the start of the protocol. Following library construction,
hybridization and capture were performed using the relevant components of
Illumina’s Rapid Capture Exome Kit and following the manufacturer’s suggested
protocol. All hybridization and capture steps were automated on the Agilent Bravo
liquid-handling system. On the basis of qPCR quantiﬁcation with probes speciﬁc to
the ends of the adapters (KAPA Biosystems), libraries were normalized to 2 nM,
and then denatured using 0.1N NaOH on the Perkin-Elmer MiniJanus. After
denaturation, libraries were diluted to 20 pM (hybridization buffer, Illumina).
Cluster ampliﬁcation of denatured templates was performed according to the
manufacturer’s protocol (Illumina) using HiSeq v3 cluster chemistry and HiSeq
2500 ﬂowcells to an average sequencing depth of 138 (Supplementary Table 1).
Flowcells were sequenced on HiSeq 2500 using v3 Sequencing-by-Synthesis
chemistry, and then analysed using RTA v.1.12.4.2 or later. Each pool of whole-
exome libraries was run on paired 76-bp runs, and an eight-base index-sequencing
read was performed to read molecular indices across the number of lanes needed to
meet coverage for all libraries in the pool. Alignments to hg19 using bwa
version 0.5.9-r16 (ref. 38) and quality control were performed using the Picard
(http://picard.sourceforge.net/) and Firehose (http://dx.doi.org/10.7908/C180514N)
pipelines at the Broad Institute. Firehose is a framework combining workﬂows for
the analysis of cancer-sequencing data. The workﬂows perform quality control,
local re-alignment, mutation calling, small insertion and deletion identiﬁcation,
rearrangement detection and coverage calculations, among other analyses. Average
coverage is listed in Supplementary Table 1. WES data have been deposited in
dbGaP (phs001091.v1.01).
Mutation calling. The MuTect algorithm (http://www.broadinstitute.org/cancer/
cga/mutect) was used to identify somatic mutations in targeted exon data31.
MuTect identiﬁes candidate somatic mutations by Bayesian statistical analysis of
bases and their qualities in the tumour and normal BAM ﬁles at a given genomic
locus. The lowest allelic fraction at which somatic mutations could be detected on a
per-sample basis was estimated based on cross-contamination level of 2%. All
somatic mutations were reviewed manually using the Integrative Genomics
Viewer32.
Somatic copy number alteration identiﬁcation. Somatic copy number altera-
tions (SCNAs) were identiﬁed from the analysis of genome-wide copy number
proﬁles of CLL and matched germline DNA, obtained using the Genomewide
Human SNP Array 6.0 (Affymetrix) according to the manufacturer’s protocol
(Genetic Analysis Platform, Broad Institute, Cambridge, MA). SNP array data were
deposited in dbGaP (phs000435.v1.p1). Alternatively, SCNAs were inferred from
the whole-exome data from the ratio of tumour read depth to the expected read
depth derived from a panel of normal samples using the ReCapSeg programme,
which is available for download (http://gatkforums.broadinstitute.org/gatk/
categories/recapseg-documentation). Allele-speciﬁc analysis allowed for the
identiﬁcation of copy neutral loss of heterozygosity (LOH) events and quantiﬁ-
cation of the homologous copy ratios using both Hapseg33 on SNP arrays and
Allelic CapSeg on exomes. Regions with germline copy number variants were
excluded from the analysis.
Deep sequencing of somatic single-nucleotide variants. When DNA was
available (Supplementary Table 1), deep sequencing was performed by targeted
resequencing using microﬂuidic PCR (Access Array System, Fluidigm). In total,
112/133 candidate somatic mutations identiﬁed in Patients 1–4 were sequenced
with this approach (Supplementary Table 3). Tumour and matched normal
samples were included in this analysis to exclude germline variants. Target-speciﬁc
primers were designed to ﬂank sites of interest and produce amplicons of
200±20 bp. Per well, molecularly barcoded, Illumina-compatible speciﬁc oligo-
nucleotides containing sequences complementary to the primer tails were added to
the Fluidigm Access Array chip together with genomic DNA samples (20–50 ng of
input) such that all amplicons for a given DNA sample shared the same index, and
PCR was performed according to the manufacturer’s instructions. From each
individual collection well from the Fluidigm chip, indexed libraries were recovered
for each sample, quantiﬁed using picogreen and then normalized for uniformity
across libraries. Resulting normalized libraries were loaded on the MiSeq
instrument and sequenced using paired-end 150-bp sequencing reads39. The mean
coverage per sample is listed in Supplementary Table 1 (range 938.9–5419.5 ).
ABSOLUTE analysis and clonal evolution mapping. ABSOLUTE pipeline was
implemented as previously described8,34 to the sequencing data to convert allelic
fractions to CFFs, accounting for sample purity and the local copy number
information. The CCFs were clustered as previously described8 to delineate distinct
subclonal populations. Phylogenetic relationships between these populations were
inferred using patterns of shared mutations and CCF, as previously described40.
The CCF of each clone was converted to clonal size (in cell number) by multiplying
the CCF by the total size of the circulating CLL population (as measured by the
ALCs per microlitre times the total blood volume). Clone-speciﬁc growth/decline
rates were then inferred by using regression applied to the measurements available
for each subclone, assuming ﬁxed exponential growth rates.
Mathematical analysis of clonal kinetics. CCFs obtained from the ABSOLUTE
analysis were combined with ALC counts to obtain estimates for the numbers of
cancer cells in each clone present at the time of sequencing, assuming 5 l as the
peripheral blood volume41. We assumed that during treatment clones either grow
or decline exponentially, with constant rates. For clones with exactly two
measurements, s.d.’s of growth rates were estimated using posterior distributions of
CCFs. For clones with more than two measurements, we report s.e.’s for growth
rates obtained from linear regression in the log domain. We estimated the number
of cells in a resistant clone at the time of initiation of ibrutinib treatment under the
assumption that the growth rate of the resistant clone remains constant during
treatment. Conﬁdence intervals are obtained using posterior distributions of CCFs.
Droplet detection of single cells with somatic gene mutations. CLL cells,
PBMC or cell lines resuspended in RPMI 1640 with 20% fetal bovine serum were
applied to polydimethylsiloxane microﬂuidic devices that were fabricated using
standard soft lithographic methods42. These microﬂuidic chips contain a co-ﬂow
droplet generator (cross-section of 35 mm2) to yield 50-mm monodisperse aqueous
drops in ﬂuorinated oil, HFE-7500 (3M, St Paul, MN) containing 2% (w/w)
Krytox-PEG diblock co-polymer surfactant (RAN Biotech, Beverly, MA). The
microﬂuidic channel walls were rendered hydrophobic by treating them with
Aquapel (PPG, Pittsburgh, PA). Cell lysis buffer (2 , 1M Tris-HCl pH 8.0, 10%
Tween-20 and 100mgml 1 proteinase K in one channel and a suspension of a
single-cell population or mixtures of cell populations are encapsulated together in
drops via co-ﬂow at a 1:1 ratio. The droplets were collected in 200 ml in a PCR tube
and covered with mineral oil. Cell lysis within the drops was achieved using the
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following conditions: 37 C for 10min, 50 C for 20min and 70 C for 10min.
Subsequently, the droplets containing single lysed cells were maintained on ice.
To amplify transcripts with the mutated alleles, the droplet suspension (at 33 pl
volume per droplet) was introduced into a microﬂuidic pico-injection device and
injected droplet by droplet with 50 ml of a 2 RT–PCR cocktail through
electrocoalescence43. The 2 RT–PCR cocktail contained 4 ml of OneStep
RT–PCR enzyme mix with 2 OneStep RT–PCR buffer (Qiagen) 800mM dNTPs,
0.6 mM forward and reverse primers for patient-speciﬁc somatic mutations
(purchased from IDT, Coralville, Iowa), 0.5 mM Taqman probe (Life Tech, Grand
Island, NY), 0.4 mgml 1 BSA and 0.4% Tween-20 (see Supplementary Table 5 for
primer and probe sequences). Droplets were spaced on the chip by oil with 2% w/w
surfactant. The device electrodes were connected to a high-voltage TREK 2210
ampliﬁer (TREK, Lockport, NY), which supplies a 100-V sine wave at a frequency
of 25 kHz. The ﬂow rate of the PCR cocktail was chosen to ensure that the buffer
would be added at B1:1 ratio on coalescence. Typical ﬂow rates fulﬁlling these
requirements were 300 ml h 1 for oil with surfactant, 60 ml h 1 for the droplets
containing lysed cells and 30 ml h 1 for the PCR cocktail. The droplets were
collected in a PCR tube and covered with mineral oil to prevent evaporation.
RT–PCR was performed using the following conditions: 50 C for 30min, 95 C for
10min, two cycles of 94 C for 15 s and 64 C for 8min, and 38 cycles of 95 C for
15 s and 62 C for 1min.
Ampliﬁed mutated transcripts within single cells were detected with
microﬂuidic-based sorting and signal detection. We re-injected the post-
ampliﬁcation drops, achieving a stream of evenly spaced drops through co-ﬂowing
of the drop suspension (ﬂow rate 15 ml h 1) and HFE-7500 oil with 1% surfactant
(ﬂow rate 180 ml h 1) into a ‘T’ junction. This stream ﬂowed through a
25 25-mm channel, and was exposed to an excitation laser (488 nm). Fluorescence
information from single cells was collected with a microscope objective and focused
to a photomultiplier tube (Hammamatsu). The pulses were acquired by a real-time
ﬁeld-programmable gate array card (National Instruments, Austin, TX), recorded
by a LabView programme and analysed in MATLAB. The pulse height was used as
the measure of droplet ﬂuorescence. The pulse width, which is the duration of time
for a drop to pass through the laser, was used as the measure of droplet size. The
sensitivity of our photomultiplier tube was sufﬁciently high to detect droplets not
containing target templates because of the intrinsic ﬂuorescence of the Taqman
probe. Cells were designated as positive of the normalized activated ﬂuorescence
was higher than the signal generated by control PBMC for healthy adult volunteers.
For detection of very rare cells, we developed a second step of droplet analysis
using digital PCR. To obtain the templates for the second-round digital PCR, 25 ml
of 1H,1H,2H,2H-perﬂuoro-1-octanol (PFO; Sigma-Aldrich, St Louis, MO) was
added to the pool of emulsion droplets and gently centrifuged to separate the
phases, such that the PCR products from the ﬁrst-round RT–PCR were in the
liquid phase. PCR products were then diluted 1,000-fold, and 1 ml of the resulting
product was encapsulated at a single template per droplet using a microﬂuidic
device that contains a ﬂow-focusing droplet maker with a cross-section of
15 25mm to generate 25-mm monodisperse aqueous drops in HFE-7500
containing 2% (w/w) surfactant. The ﬂow is driven by applying a  0.4 PSI vacuum
at the outlet. The templates were then ampliﬁed using a 25-ml PCR cocktail
containing 1 ml of OneStep RT–PCR enzyme mix with 1OneStep RT–PCR buffer
(Qiagen), 400 mM dNTPs, 0.25 mM forward and reverse primers, 0.24 mM Taqman
probe, 0.2 mg ml 1 BSA and 0.2% Tween-20 using the following RT–PCR protocol:
95 C for 10min, 40 cycles of two cycles of 94 C for 15 s, 64 C for 8min and 38
cycles of 95 C for 15 s, 62 C for 1min. To quantify the mutant cells in the original
sample, we compared ﬂuorescence obtained from the experimental sample against
a standard curve generated by the ﬂuorescence detection from known mixtures of
speciﬁc cell lines generated to express the gene of interest with or without the
mutation of interest (see Supplementary Table 4 for conditions of cloning these
plasmids; Fig. 3e).
RNA-seq. For generation of RNA libraries, 5 mg of total RNA was poly-A-selected
using oligo-dT beads to extract the desired mRNA, treated with DNase and then
processed with SPRI beads as per the manufacturer’s protocol. The selected Poly-A
RNA was then fragmented into 450-bp fragments in an acetate buffer at high heat.
Fragmented RNA was SPRI-cleaned and primed with random hexamers before
ﬁrst-strand cDNA synthesis. To prevent hair-pinning, the ﬁrst strand was reverse-
transcribed off the RNA template in the presence of Actinomycin D, followed by
SPRI bead puriﬁcation. The RNA in the RNA–DNA complex was then digested
using RNase H. The second strand was next synthesized with a dNTP mixture, in
which dTTPs were replaced with dUTPs. After another round of SPRI bead
puriﬁcation, the resultant cDNA was processed per Illumina library construction
according to the manufacturer’s protocol (end repair, phosphorylation, adenylation
and adaptor ligation with indexed adaptors). SPRI-based size selection was
performed to remove adaptor dimers present in the newly constructed cDNA
library. Libraries were treated with uracil-speciﬁc excision reagent to nick the
second strand at every incorporated uracil (dUTP). Subsequently, libraries were
enriched with eight cycles of PCR using the entire volume of sample as template.
Following enrichment, the library was quantiﬁed using picogreen, and the fragment
size is measured (Agilent Bioanalyzer). Samples were pooled and sequenced using
either 76 or 101 bp paired-end reads. RNA-seq BAMs were aligned to the hg19
genome using the TopHat suite. Each somatic base substitution detected by WES
was compared with reads at the same location in RNA-seq. On the basis of the
number of alternate and reference reads, a power calculation was obtained with
beta-binomial distribution (power threshold used was greater than 80%). Mutation
calls were deemed validated if two or greater alternate allele reads were observed in
RNA-seq at the site, as long as RNA-sseq was powered to detect an event at the
speciﬁed location (power 40.8). RNA-seq data were deposited in dbGaP
(phs001091.v1.01).
Generation of stable cell lines. To generate stable cell lines expressing wild-type
and mutant PLCG2 and RPS15, cDNA fragments around the mutation sites of
interest were cloned (see Supplementary Table 4 for mutation sites, primers and
vectors). Mutations were introduced into the cDNA fragments through site-
directed mutagenesis (Quickchange II Site-Directed Mutagenesis Kit, 200523-5,
Agilent Technology). The vectors were linearized by MfeI, and transfected into
murine 300.19 cells through electroporation. The transfected cells were selected
with antibiotics for 2 weeks to generate the stable cell lines.
Microﬂuidics-based single-cell detection of mutations. Fluorescence-activated
cell sorting-sorted CD19þCD5þ7AAD single cells were collected and processed
through the pre-ampliﬁcation step as described in ref. 44, with the exception that
Reverse Transcription Master Mix (Fluidigm 100-6297) was used in the reverse
transcriptase step and 5 PreAmp Master Mix (Fluidigm 100-5744) was used in
the pre-ampliﬁcation step. The use of a 5 formulation enabled reducing the
volume of the pre-ampliﬁcation reaction to 10 ml, which enhanced sensitivity.
Paired mutated- and normal-allele-speciﬁc primers were designed using a nested
design, with outer primers for pre-ampliﬁcation and inner primers for qPCR
detection, such that ampliﬁcation of the mutated alleles with the two assays yielded
a difference of at least six cycles. Each assay consisted of an allele-speciﬁc
SuperSelective primer45 and a common primer shared by the normal and mutation
assay. The sequences of the primers used are provided in Supplementary Table 5.
Single-cell cDNA was submitted for multiplexed pre-ampliﬁcation with a mixture
of all the outer primers for patient-speciﬁc, mutation-speciﬁc assays at a ﬁnal
concentration of 50 nM each primer. Pre-ampliﬁed cDNA samples from single cells
were then analysed with qPCR using 96.96 Dynamic Array integrated ﬂuidic
circuits (IFCs) and the Biomark HD System from Fluidigm as per the
manufacturer’s procedures. To detect somatic mutations, a Master Mix was
prepared consisting of Fast-Plus EvaGreen Master Mix (2 , 420 ml) with Low
ROX (Biotium 31014), DNA-binding dye sample loading reagent (20 , 42ml),
500mM EDTA (1.5 ml) and H2O (16.5ml) with 4 ml of this mix dispensed per well
of a 96-well assay plate. Three microlitres of pre-ampliﬁed cDNA sample were
added to each well, and the plate was brieﬂy vortexed and centrifuged. Following
priming of the IFC in the IFC Controller HX, 5 ml of the cDNA sampleþMaster
Mix were dispensed to each Sample Inlet of the 96.96 IFC. After loading the assays
and samples into the IFC Controller HX, the chip was transferred to the Biomark
HD and PCR was performed (using protocol GE Fast 96 96 PCRþMelt v10.pcl).
The thermal cycling protocol consists of a Thermal Mix of 70 C, 40min; 66 C,
30 s, hot start at 95 C, 2min, PCR cycle of two cycles of 96 C, 5 s; 64 C, 480 s,
PCR cycle of 30 cycles of 96 C, 5 s; 62 C, 30 s and melting using a ramp from 60 to
95 C at 1 C per 3 s. Data were analysed processing with the Fluidigm Real-Time
PCR Analysis software, which uses the Linear (Derivative) Baseline Correction
Method and the Auto (Global) Ct Threshold Method. For each patient sample, two
independent IFCs were run and the results consolidated by averaging the technical
replicates.
To call mutations, we ﬁrst modelled the background level of expression of the
mutated allele by linear regression through assessment of normal B cells known to
have absence of the mutation of interest. We then calculated the fraction of the
normalized mutant allele over normal plus normalized mutant allele. Cells with
this normalized fractional mutant allele below 0.15 were called as ‘normal’, while
cells with this normalized fractional mutant allele greater than 0.3 were called as
‘mutant’, and anything in between were called as ‘unclear.’ A threshold of 0.3
was determined by ad hoc assessment on the negative controls. We restricted
subsequent analysis to cells for which we could conﬁdently call ‘normal’ or ‘mutant’
status. Cells for which we did not detect either the mutant or the normal alleles,
yielding a normalized mutant allele level of 0/0, were excluded.
In vitro viability experiments. After obtaining informed consent, peripheral blood
samples were obtained from patients fulﬁlling diagnostic and immunophenotypic
criteria for CLL at MDACC or at Dana-Farber Cancer Institute (DFCI). Consent
for samples used in this study was obtained in accordance with the Declaration of
Helsinki on protocols that were reviewed and approved by the IRBs of MDACC or
Dana-Farber/Harvard Cancer Center. In vitro testing of cell viability of CLL cells
with or without del(8p) (veriﬁed with a FISH-speciﬁc probe) following exposure to
ibrutinib and/or TRAIL was performed by ﬂow cytometry using Annexin V and
propidium iodide staining. Fresh or thawed cryopreserved mononuclear cells were
treated with 1 mM ibrutinib (Selleck Chemicals, Houston, TX) and/or Super Killer
TRAIL (ENZO Biochem, New York, NY), and cell viability was assessed in CD19-
positive CLL cells at 24-h intervals on an LSR Fortessa ﬂow cytometer (BD Bios-
ciences, San Diego, CA). Data analysis was performed on the time point for each
sample that exhibited viability closest to 75% in untreated cells. Cell viability was
measured by % viable (Annexin V (BD Biosciences) and propidium iodide (Sigma,
St Louis, MO) negative) or absolute live cell counts. Absolute live cell counts were
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obtained by supplementing cells before ﬂow cytometric analysis with CountBright
Absolute Counting Beads (Life Technologies) and acquiring each sample based on
bead count. The two different methods of cell viability analysis yielded comparable
results (Supplementary Fig. 6B). Data were presented as % viable, unless otherwise
indicated. Cell surface TRAIL expression was detected using the allophycocyanin
(APC)-conjugated anti-human CD261 (DR4) antibody (clone DJR1, Biolegend,
San Diego, CA).
TRAIL plasma levels. TRAIL plasma levels were measured using Quantikine
solid-phase ELISA Kits according to the manufacturer’s instructions (R&D Sys-
tems, Minneapolis, MN). The absorbance was recorded (ELx808 microplate reader,
Bio-Tek Instruments), and data collection and analysis were performed using the
Gen5 software Version 1.08 (Bio-Tek Instruments). Plasma samples were collected
in tubes containing EDTA as an anticoagulant. As per the manufacturer, the mean
normal TRAIL level in plasma is 82 pgml 1 (range: 34–163 pgml 1).
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